Company / Current Assets per Share
Neurocrine Biosciences Current Assets per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets per Share
$25.38
FY2025
5-year range
$10.40 / $25.38
FY2021-FY2025
Trend
+45.2%
vs FY2024
Sector context
#21 of 212
Health Care
What the data says
Among 212 Health Care companies, Neurocrine Biosciences is in the top 10% for current assets per share. Current Assets per Share has increased for 4 consecutive years, from $10.40 in FY2021 to $25.38 in FY2025.
Based on SEC 10-K filings.
25.38 in FY2025 with a 5-year CAGR of +18.2%. Top quartile in the Health Care sector.
Improved from $16.65 to $25.38 over the past 2 years.
Health Care sector context is included.
Current Assets per Share over time
Growth rates
- 3-Year CAGR
- +18.3%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Sector benchmark
-80.9% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's current assets per share has grown for 4 consecutive years.
- In FY2025, current assets per share increased 45.2% year-over-year.
- Ranks #21 out of 212 companies in the Health Care sector.
- Lowest current assets per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.38 | +45.2% |
| FY2024 | $17.47 | +4.9% |
| FY2023 | $16.65 | +8.7% |
| FY2022 | $15.32 | +47.2% |
| FY2021 | $10.40 | -5.5% |
| FY2020 | $11.01 | +20.3% |
| FY2019 | $9.15 | +10.2% |
| FY2018 | $8.31 | +30.1% |
| FY2017 | $6.39 | +77.5% |
| FY2016 | $3.60 | -28.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026